# Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)

> **NCT04795752** · NA · COMPLETED · sponsor: **Sight Sciences, Inc.** · enrollment: 345 (actual)

## Conditions studied

- Dry Eye
- Meibomian Gland Dysfunction

## Interventions

- **DEVICE:** TearCare System
- **DRUG:** Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion

## Key facts

- **NCT ID:** NCT04795752
- **Lead sponsor:** Sight Sciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-28
- **Primary completion:** 2024-09-23
- **Final completion:** 2024-09-23
- **Target enrollment:** 345 (ACTUAL)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04795752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04795752, "Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04795752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*